The stock price of Eterna Therapeutics Inc (NASDAQ: ERNA) has dropped by -8.70 compared to previous close of 1.15. Despite this, the company has seen a fall of -13.93% in its stock price over the last five trading days. globenewswire.com reported 2024-05-10 that The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells The presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene + Cell Therapy, taking place in Baltimore, Maryland.
Is It Worth Investing in Eterna Therapeutics Inc (NASDAQ: ERNA) Right Now?
The 36-month beta value for ERNA is also noteworthy at 4.45. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ERNA is 2.79M, and at present, short sellers hold a 1.31% of that float. The average trading volume of ERNA on October 01, 2024 was 19.98K shares.
ERNA’s Market Performance
ERNA stock saw a decrease of -13.93% in the past week, with a monthly decline of -42.62% and a quarterly a decrease of -44.30%. The volatility ratio for the week is 25.79%, and the volatility levels for the last 30 days are 12.31% for Eterna Therapeutics Inc (ERNA). The simple moving average for the past 20 days is -26.95% for ERNA’s stock, with a -42.93% simple moving average for the past 200 days.
ERNA Trading at -36.79% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.00% of loss for the given period.
Volatility was left at 12.31%, however, over the last 30 days, the volatility rate increased by 25.79%, as shares sank -43.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.16% lower at present.
During the last 5 trading sessions, ERNA fell by -13.93%, which changed the moving average for the period of 200-days by -33.02% in comparison to the 20-day moving average, which settled at $1.3972. In addition, Eterna Therapeutics Inc saw -41.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -135.73 for the present operating margin
- -10.99 for the gross margin
The net margin for Eterna Therapeutics Inc stands at -147.65. The total capital return value is set at -0.6. Equity return is now at value -1154.18, with -51.20 for asset returns.
Based on Eterna Therapeutics Inc (ERNA), the company’s capital structure generated 2.84 points at debt to capital in total, while cash flow to debt ratio is standing at -1.25. The debt to equity ratio resting at -1.54. The interest coverage ratio of the stock is -10.55.
Currently, EBITDA for the company is -19.55 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 322.84. The receivables turnover for the company is 0.71for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.37.
Conclusion
In summary, Eterna Therapeutics Inc (ERNA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
